Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-x L inhibitors on human ovarian carcinoma cells

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Lincet, Hubert ^a,b,c   Kafara, Perrine ^a,b,c   Giffard, Florence ^a,b,c   Abeilard Lemoisson, Edwige ^a,b,c   Duval, Maryline ^a,b,c   Louis, Marie Hélène ^a,b,c   Poulain, Laurent ^a,b,c   Icard, Philippe ^a,b,c,d  

^a NORMANDIE UNIVERSITÉ   (France)

^b BioTICLA EA 4656   (France)

^c CLCC Centre de Lutte Contre le Cancer François Baclesse   (France)

^d UNIVERSITÉ DE CAEN   (France)

Author keywords

Bcl xL; Cell death; Citrate; Mcl 1; Ovarian cancer

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CITRIC ACID; PROTEIN BCL XL; PROTEIN MCL 1; SMALL INTERFERING RNA;

ARTICLE; CARCINOMA CELL; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84885790189     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-72     Document Type: Article

References (35)

1. Advanced ovarian cancer. Chi DS, Sabbatini P, Curr Treat Options Oncol 2000 1 139 146 10.1007/s11864-000-0058-1 12057051
2. Management of recurrent ovarian cancer: evidence-based decisions. Salom E, Almeida Z, Mirhashemi R, Curr Opin Oncol 2002 14 519 527 10.1097/00001622- 200209000-00008 12192271
3. Apoptosis in cancer: key molecular signaling pathways and therapy targets. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A, Acta Oncol 2009 48 811 821 10.1080/02841860902974175 19513886
4. Bcl-2 family proteins and cancer. Yip KW, Reed JC, Oncogene 2008 27 6398 63406 10.1038/onc.2008.307 18955968
5. The BCL-2 protein family: opposing activities that mediate cell death. Youle RJ, Strasser A, Nat Rev Mol Cell Biol 2008 9 47 59 10.1038/nrm2308 18097445
6. The BCL-2 family reunion. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR, Mol Cell 2010 37 299 310 10.1016/j.molcel.2010.01.025 20159550
7. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Frenzel A, Grespi F, Chmelewskij W, Villunger A, Apoptosis 2009 14 584 596 10.1007/s10495-008-0300-z 19156528
8. Expression of bcl-2 family members in malignant pleural mesothelioma. O'Kane SL, Pound RJ, Campbell A, Chaudhuri N, Lind MJ, Cawkwell L, Acta Oncol 2006 45 449 453 10.1080/02841860500468927 16760181
9. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Brotin E, Meryet-Figuière M, Simonin K, Duval RE, Villedieu M, Leroy-Dudal J, et al. Int J Cancer 2010 126 885 895 19634140
10. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le GS, Avet-Loiseau H, et al. Leukemia 2005 19 1248 1252 10.1038/sj.leu.2403784 15902294
11. Citrate induces apoptotic cell death: a promising Way for treating gastric carcinoma? Lu Y, Zhang XD, Lan J, Huang G, Varin E, Lincet H, et al. Anticancer Res 2011 31 797 805 21498699
12. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Varin E, Denoyelle C, Brotin E, Meryet-Figuiere M, Giffard F, Abeilard E, et al. Carcinogenesis 2010 31 984 993 10.1093/carcin/bgq026 20142415
13. Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells. Simonin K, Brotin E, Dufort S, Dutoit S, Goux D, N'diaye M, et al. Mol Cancer Ther 2009 8 3162 3170 10.1158/1535-7163.MCT-09-0493 19887550
14. siPGK1 Sensitizes chemoresistant human ovarian cancer cell lines to cisplatin. Lepleux C, Abeilard-Lemoisson E, Duval M, Icard P, Lincet H, Anticancer Res 2012 32 4277 4286 23060548
15. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Simonin K, N'diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, et al. Apoptosis 2013 18 492 508 10.1007/s10495-012-0799- x 23344663
16. Comparative 2D-DIGE proteomic analysis of ovarian carcinoma cells: toward a reorientation of biosynthesis pathways associated with acquired platinum resistance. Lincet H, Guével B, Pineau C, Allouche S, Lemoisson E, Poulain L, et al. J Proteomics 2012 75 1157 1169 10.1016/j.jprot.2011.10.030 22100381
17. The impact of O2 availability on human cancer. Bertout JA, Patel SA, Simon MC, Nat Rev Cancer 2008 8 967 975 10.1038/nrc2540 18987634
18. HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Monti E, Gariboldi MB, Curr Mol Pharmacol 2011 4 62 77 20958262
19. Hypoxia in cancer: significance and impact on clinical outcome. Vaupel P, Mayer A, Cancer Metastasis Rev 2007 26 225 239 10.1007/s10555-007-9055-1 17440684
20. A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Icard P, Lincet H, Biochim Biophys Acta 1826 2012 423 433
21. Understanding the central role of citrate in the metabolism of cancer cells. Icard P, Poulain L, Lincet H, Biochim Biophys Acta 1825 2012 111 116
22. Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push? Del GM V, Letai A, Adv Exp Med Biol 2008 615 159 175 10.1007/978-1-4020-6554-5-8 18437895
23. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Liu JR, Fletcher B, Page C, Hu C, Nunez G, Baker V, Gynecol Oncol 1998 70 398 403 10.1006/gyno.1998.5125 9790794
24. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Bock BC, et al. Oncogene 2008 27 6646 6656 10.1038/onc.2008.259 18663354
25. Citrate kills tumor cells through activation of apical caspases. Kruspig B, Nilchian A, Orrenius S, Zhivotovsky B, Gogvadze V, Cell Mol Life Sci 2012 69 4229 4237 10.1007/s00018-012-1166-3 23052210
26. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. Nature 2005 435 677 681 10.1038/nature03579 15902208
27. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY, et al. Mol Cell Biol 2007 27 4006 4017 10.1128/MCB.00620-06 17387146
28. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR, Mol Cell 2006 21 749 760 10.1016/j.molcel. 2006.02.009 16543145
29. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, et al. Genes Dev 2003 17 1475 1486 10.1101/gad.1093903 12783855
30. Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Zhao Y, Altman BJ, Coloff JL, Herman CE, Jacobs SR, Wieman HL, et al. Mol Cell Biol 2007 27 4328 4339 10.1128/MCB.00153-07 17371841
31. Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control. Poulain L, Lincet H, Duigou F, Deslandes E, Sichel F, Gauduchon P, et al. Int J Cancer 1998 78 454 463 9797134
32. Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Michels J, O'Neill JW, Dallman CL, Mouzakiti A, Habens F, Brimmell M, et al. Oncogene 2004 23 4818 4827 10.1038/sj.onc.1207648 15122313
33. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. Han J, Goldstein LA, Gastman BR, Rabinowich H, J Biol Chem 2006 281 10153 10163 10.1074/jbc.M510349200 16478725
34. Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation. Kim SM, Yun MR, Hong YK, Solca F, Kim JH, Kim HJ, et al. Mol Cancer Ther 2013 Epub ahead of print
35. Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival. Yi CH, Pan H, Seebacher J, Jang IH, Hyberts SG, Hefffron GJ, et al. Cell 2011 146 607 620 10.1016/j.cell.2011.06.050 21854985